Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Therapies

Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data

  • Omar Chebbo
  • François Roubille
  • Jean-Luc Faillie
  • Nicolas Chapet
  • Pascale Palassin
Open at sourcePDFDOICite

Related

  1. Cardiac adverse event signals of Bruton’s tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study
    Tingting Zhang, Ganggang Wang, Xuejing Yang +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCPMC
  2. Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
    Jizhou Liang, Lulong Bo, Xiaoyong Miao +4
    BMC pharmacology & toxicologyPeer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyEurope PMC
  3. Similarity-based profiling of pharmacovigilance data for drug safety pattern discovery
    Seongjae Park, SeongJin Wi, Heeseon Jo +3
    The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of PharmacologyPeer-reviewedCC BY-NC 4.0Full textPharmacology & toxicologyPMC
  4. Pharmacovigilance of Integrase Strand Transfer Inhibitors (INSTIs) in Botswana: Safety Signals, Report Completeness, and Causality Assessment
    P. Pono, V. Cheng, A. M. Jones
    medRxivPreprintCC BYFull textEpidemiology & public healthmedRxiv
  5. BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study
    Emilien Ezine, Angélique da Silva, Safa Idoudi +5
    TherapiesPeer-reviewedCC BY-NC-NDPharmacology & toxicologyHAL

Cite

BibTeXRIS
BibTeX
@article{chebbo2026distinct,
  title = {{Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data}},
  author = {Omar Chebbo and François Roubille and Jean-Luc Faillie and Nicolas Chapet and Pascale Palassin},
  journal = {Therapies},
  year = {2026},
  month = sep,
  doi = {10.1016/j.therap.2026.07.007},
  url = {https://hal.science/hal-05755542v1},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data
AU  - Omar Chebbo
AU  - François Roubille
AU  - Jean-Luc Faillie
AU  - Nicolas Chapet
AU  - Pascale Palassin
PY  - 2026
DA  - 2026/09/29
JO  - Therapies
DO  - 10.1016/j.therap.2026.07.007
UR  - https://hal.science/hal-05755542v1
SN  - 0040-5957
SN  - 1958-5578
ER  -